Abstract Activity of the A 3 adenosine receptor (AR) allosteric m odulators L UF600 0 (2-cyclohexyl-N -(3,4-dichlorophenyl)-1H-imidazo [4,5-c]quinolin-4-amine) and LUF6096 (N-{2-[(3,4-dichlorophenyl)amino]quinolin-4-yl}cyclohexanecarbox-amide) was compared at four A 3 AR species homologs used in preclinical drug development. In guanosine 5′-[γ-[ 125 I]I-AB-MECA binding kinetics. Homology modeling suggested interaction between speciesvariable EL1 and agonist-contacting EL2. These results indicate that A 3 AR allostery is species-dependent and provide mechanistic insights into this therapeutically promising class of agents.
I]I-AB-MECA) binding assays, we hypothesize that potency reduction is explained by an allosterically induced slowing in orthosteric ligand binding kinetics that reduces the rate of formation of ligand-receptor complexes. Mutation of four amino acid residues of the human A 3 AR to the murine sequence identified the extracellular loop 1 (EL1) region as being important in selectively controlling the allosteric actions of LUF6096 on [
125 I]I-AB-MECA binding kinetics. Homology modeling suggested interaction between speciesvariable EL1 and agonist-contacting EL2. These results indicate that A 3 AR allostery is species-dependent and provide mechanistic insights into this therapeutically promising class of agents. 
Introduction
Selective A 3 adenosine receptor (AR) agonists are currently being developed as pharmacological therapy for a number of inflammatory diseases including rheumatoid arthritis, psoriasis, and cancer [1] . However, the full therapeutic benefit of these drugs could be limited by dose-limiting side effects [2] . Clinical development of A 3 AR ligands is further challenged by substantial differences in A 3 AR pharmacology among species [3] [4] [5] [6] . This complication hinders assessment of therapeutic efficacy of A 3 AR ligands in non-primate models of human disease. Allosteric modulators of G protein-coupled receptors (GPCRs) are ligands that alter the affinity or intrinsic activity of orthosteric ligands by interacting with a distinctly different binding site on the receptor [7] [8] [9] [10] . From a therapeutic perspective, allosteric modulators have the advantage of regulating activity of an endogenous ligand in a spatially and temporally specific manner [7] [8] [9] [10] . Allosteric ligands typically mediate their effects by inducing conformational changes in the receptor that alter orthosteric agonist binding affinity and/or intrinsic activity thereby causing positive or negative allosteric modulation. These effects can vary depending on the nature of the orthosteric ligand (Bprobe dependence^) and have the capability to selectively modulate specific intracellular signaling pathways (Bsignaling bias^).
Several classes of compounds have been reported to be allosteric modulators for the human A 3 AR, including the imidazoquinolinamines and the 2,4-disubstituted quinolines [11] [12] [13] [14] [15] [16] [17] [18] . Derivatives of these two chemical classes function as positive allosteric modulators (PAMs) that increase the intrinsic activity of orthosteric agonists, while tending to reduce potency. 2-Cyclohexyl-N-(3,4-dichlorophenyl)-1H-imidazo [4,5-c] quinolin-4-amine (LUF6000) (Fig. 1 ) emerged from structure-activity relationship (SAR) studies of the imidazoquinolinamine template as having a pronounced effect to increase agonist efficacy with less propensity to decrease potency ( Fig. 1 ; [16] ) and to exhibit selectivity versus the other three AR subtypes [15, 16] . Modification of LUF6000 involving scission of the imidazole ring led to the development of the 2,4-disubstituted quinoline LUF6096 (Fig. 1) , which similarly retained desirable allosteric effects and A 3 AR selectivity [17] . Both of these compounds have begun to be tested for therapeutic efficacy in animal models of disease [19, 20] . These compounds were developed for activity at the human A 3 AR, however, and it remains to be determined whether they exhibit similar modulating activity at the A 3 AR from other species.
The goal of this investigation was to characterize the modulatory activity of LUF6000 and LUF6096 for the A 3 AR from a panel of animal species commonly used in drug development research. Functional modulation was assessed using a guanosine 5′[γ-[ 
Materials and methods

Materials
Cell culture reagents were purchased from Invitrogen (Carlsbad, CA). [ 35 S]GTPγS (specific activity 1250 Ci/ mmol) and carrier-free Na 125 I (2200 Ci/ml) were from PerkinElmer (Boston, MA). LUF6000 and LUF6096 were synthesized as reported [16, 17] . Plasmid purification kits were purchased from Qiagen (Valencia, Ca). Adenosine deaminase (ADA) was obtained from Roche Applied Sciences (Indianapolis, IN) and glass fiber filters (GF/B and GF/C) were obtained from Whatman (Sanford, ME). All remaining drugs and reagents were purchased from Sigma-Aldrich (St. Louis, MO).
Creation of stable HEK 293 cell lines expressing A 3 ARs
Full-length dog, rabbit, and mouse A 3 AR cDNAs subcloned into the mammalian expression vector pCDNA3.1 were obtained, as previously described [21] [22] [23] . The human A 3 AR Fig. 1 Chemical structures of A 3 AR allosteric modulator compounds used in the present investigation cDNA in pCDNA3.1 was purchased from the cDNA Resource Center (www.cdna.org). Site-directed mutations (G75Q/I76V/T77K/I78M) were introduced into the human A 3 AR cDNA using the QuikChange Site-Directed Mutagenesis kit (Stratagene), according to the manufacturer's instructions. The following primers were used to create the mutations: 5′-GCC TTT GGC CAT TGT TGT CAG CCT  GCA GGT CAA AAT GCA CTT CTA CAG CTG CCT  TTT TAT GA-3′ and 5′-TCA TAA AAA GGC AGC TGT  AGA AGT GCA TTT TGA CCT GCA GGC TGA CAA  CAA TGG CCA AAG GC-3′ . Following amplification in Escherichia coli, plasmids were purified using Qiagen (Valencia, CA) purification kits and sequenced through the entire coding region to establish the presence of the desired mutations and the absence of unintended mutations potentially generated during the amplification steps. The plasmids were transfected into human HEK 293 cells using Lipofectamine 2000 reagent (Invitrogen) and selected with 2 mg/ml of G418. Cell lines derived from individual clones were maintained in cell culture media (Dulbecco's modified Eagle's medium with 10% fetal bovine serum and antibiotics) containing 0.6 mg/ml G418. The level of expression of the receptors in each of the cell lines was equivalent based on saturation radioligand binding analyses (not shown).
Membrane preparations
Cell membranes were prepared as described previously [16, 17, 20] . Briefly, HEK 293 cells stably expressing recombinant wild-type or mutant human A 3 ARs were washed in phosphate-buffered saline followed by homogenization in hypotonic lysis buffer containing Tris-HCl buffer (50 mM, pH 7.4) containing 1 mM EDTA and 5 mM MgCl 2 and then centrifuged at 27,000×g for 30 min at 4°C. Cell pellets were washed twice in the same buffer, after which the resultant pellets were re-suspended in 50 mM Tris-HCl buffer (pH 7.4) containing 10% sucrose and stored at − 80°C. Because the modulators failed to increase [ 35 S]GTPγS binding in preliminary studies with the mouse A 3 AR using crude P1 preparations, for some studies, plasma membranes were enriched by preparing P2 pellets. Cells were homogenized in lysis buffer containing 10% sucrose and centrifuged at 500×g for 10 min to remove nuclear and other cellular debris. The pellet was re-suspended in sucrose buffer and centrifuged again at 500×g. The pooled supernatants were diluted at least threefold, pelleted, and washed twice by centrifugation at 27,000×g for 30 min in 50 mM Tris-HCl buffer (pH 7.4). The resultant pellets were re-suspended and frozen in sucrose buffer. Adenosine deaminase (3 U/ml) was also included in all assays except those examining the effects of adenosine. Then, reactions were started by addition of the membrane suspension (5 μg protein) to the tubes and carried out in quadruplicate for 2 h at room temperature. In studies with the modulators, the membranes were pre-incubated with the compounds for 30 min prior to initiating the assay. The reactions were stopped by rapid filtration through Whatman GF/B filters presoaked in 50 mM Tris-HCl buffer (pH 7.4) containing 5 mM MgCl 2 and 0.02% CHAPS. The filters were washed three times with 3 ml of wash buffer (10 mM Tris-HCl and 1 mM MgCl 2 , pH 7.4, 4°C), and radioactivity trapped in the filters was measured by liquid scintillation counting. Non-specific binding of The reactions were incubated at room temperature for the times indicated after which bound and free radioligands were separated by rapid filtration through GF/C glass fiber filters. Radioactivity trapped in the filters was measured using a gamma counter. For dissociation studies, [
125 I]I-AB-MECA (~0.3 nM) was incubated with HEK 293 cell membranes (50 μg) expressing ARs for 2 h at room temperature in binding buffer (100 μl), after which the assay was initiated by the addition of 100 μM adenosine-5′-Nethylcarboxamide (NECA, a nonselective agonist) along with the enhancer compounds or equivalent vehicle. The time-course of dissociation of specific [
125 I]I-AB-MECA binding was measured by rapid filtration at the indicated time intervals. For association/equilibration binding assays, membranes (50 μg) were incubated with [
125 I]I-AB-MECA (~0.3 nM) and the modulator compounds for the indicated times. For all assays, non-specific binding was determined by incubation in the presence of 100 μM NECA. [
125 I]I-AB-MECA was prepared by radioiodination of AB-MECA using the chloramine-T method [21, 24, 25] .
Molecular modeling
A 3 ARs homology models Homology models of the human A 3 AR, mouse A 3 AR, and mEL1-hA 3 AR were built based on the human A 2A AR crystal structure of highest available resolution (PDB ID: 4EIY; [26] ) and by using the alignment and homology modeling tools implemented in the MOE suite [27] . In particular, A 3 AR homology models were built using the automated Homology Modeling protocol. The AMBER99 force field was used for protein modeling and the Protonate 3D methodology was used for protonation state assignment [28] . The final models were refined through energy minimization until a root mean square (RMS) gradient of 0.1 kcal/ mol/Å was achieved. The stereochemical quality of the models was checked using several tools (Ramachandran plot; backbone bond lengths, angles, and dihedral plots; clash contacts report; rotamer strain energy report) implemented in the MOE suite.
Loop refinement For the final A 3 AR models, EL1 and EL2 were subjected to refinement by means of the Prime [29] package portion of the Schrödinger Suite [30] to better explore their conformational space. The two loops were cooperatively refined in pairs using an implicit membrane whose orientation and thickness were derived from the spatial arrangement of the human A 2A AR structure stored in the Orientations of Proteins in Membranes (OPM) database [31] . For the human A 3 AR model, EL1 was refined from Ser73 to His79 and EL2 from Gly148 to Cys166. Corresponding residues were refined for the other A 3 AR models.
Molecular docking of Cl-IB-MECA at the A 3 AR The Cl-IB-MECA structure was built using the builder tool implemented in the MOE suite [27] and subjected to energy minimization using the MMFF94x force field, until a RMS gradient of 0.05 kcal/mol Å was achieved. A homology model of the human A 3 AR was built based on an agonist-bound human A 2A AR crystal structure (PDB ID: 3QAK; [32] ) following the same procedure described above. Molecular docking of the ligand at the human A 3 AR model was performed by means of the Glide [33] package portion of the Schrödinger Suite [30] . The docking site was defined using key residues in the binding pocket of the human A 3 AR model, namely Phe (EL2), Asn (6.55), Trp (6.48), and His (7.43), and a 20 Å × 20 Å × 20 Å box was centered on those residues. Docking of the ligand was performed in the rigid binding site using the extra precision (XP) protocol. The top scoring docking conformations were subjected to visual inspection and comparison with the nucleoside crystallographic pose at the human A 2A AR [32] to select the final binding conformation. Due to lack of knowledge of the binding pocket, we did not attempt docking analyses with the allosteric modulators at this time.
Data analysis
EC 50 and E max values were calculated by fitting the data to: E = (E max × x) / (EC 50 + x), in which x is the concentration of the test compound. In the kinetic binding assays, dissociation rate constants were determined by fitting the specific binding d a t a t o a t w o -p h a s e e x p o n e n t i a l d e c a y m o d e l :
, where Y o denotes specific binding at time 0, f 1 and f 2 denote the fraction of receptors in the two phases, k 1 and k 2 denote the dissociation rate constants, and t denotes the elapsed time. For association assays, association binding rates were determined by fitting the specific binding data to a one-phase exponential association model:
, where Y max denotes maximal binding and k denotes the observed association rate constant. The association half-time was calculated as 0.693/k. All values were statistically compared using an unpaired Student's t test or a one-way ANOVA followed by Student's t test with the Bonferroni correction, as appropriate. All values are presented as the mean ± SEM. A p value < 0.05 was considered to be statistically significant.
Results [ 35 S]GTPγS binding
In previous functional studies with the human A 3 AR [15, 17] , both LUF6000 and LUF6096 have been shown to increase the maximal efficacy of the A 3 AR agonist 2-chloro-N 6 -(3-iodobenzyl)-adenosine-5′-N-methylcarboxamide (Cl-IB-MECA). As shown in Fig. 2 , this was confirmed in the present study using the [ 35 S]GTPγS binding assay. In the presence of 10 μM of either LUF6000 or LUF6096, the E max of Cl-IB-MECA was increased~2-3-fold, while its EC 50 was increased 5-6-fold. Neither of the compounds directly stimulated [ 35 S]GTPγS binding, supporting an allosteric mechanism. Thus, with the human A 3 AR, both compounds function as PAMs with respect to efficacy enhancement but also slightly reduce agonist potency. Similar findings were observed in assays with the dog A 3 AR (Fig. 2) , whereby the compounds increased the efficacy of Cl-IB-MECA~2-3-fold while decreasing its potency (5-6-fold). In assays with the rabbit A 3 AR, however, the efficacy of Cl-IB-MECA was increased without a reduction in potency, and in assays with the mouse A 3 AR, no enhancement was detected (Fig. 2) . A nearly identical profile was observed among the species with LUF6096 (10 μM) on efficacy and potency in assays using adenosine as the orthosteric agonist (Table 1) . To compare the potency of the enhancers among the different species, concentrationresponse curves with LUF6096 were conducted in the presence of a maximal concentration (10 μM) of Cl-IB-MECA. As shown in Fig. 3 , the calculated EC 50 values for LUF6096 for the responding species (human, dog, rabbit) differed only within a factor of 3.
Due to lack of an effect of the modulators on mouse A 3 ARs, we repeated the [ 35 S]GTPγS binding assays using enriched P2 membrane preparations (see BMaterials and methods^). As shown in Fig. 4 , in these experiments, we observed a small efficacy enhancing effect of both modulator compounds. In the presence of 10 μM of either LUF6000 or LUF6096, the E max of Cl-IB-MECA was increased 20-30%, with no change in the EC 50 . Similarly, LUF6096 produced a detectable efficacy enhancing effect (46%) in assays using adenosine as the orthosteric agonist (Fig. 4) . The EC 50 of LUF6096 to produce efficacy enhancement, determined from concentration-response curves in the presence of 10 μM Cl-IB-MECA, was calculated to be 1.33 ± 0.83 μM (n = 5), suggesting reduced (~25-fold) potency at mouse A 3 ARs compared to the other species. Overall, these observations indicate that the modulatory effects of LUF6000 and LUF6096 vary among the species tested with respect to efficacy enhancement, potency, and the propensity to reduce agonist potency. Fig. 5 , and the calculated dissociation rate constants along with the fraction of receptors for the slow phase (high-affinity state) are reported in Table 2 . At a concentration of 10 μM, both LUF6000 and LUF6096 reduced the rate of dissociation of [ cell membranes expressing human, canine, rabbit, or mouse A 3 ARs. Assays were conducted as described in Fig. 2 Based on these findings, we utilized a hybrid association/ equilibrium binding experiment to efficiently compare activity of the modulators on [ Participation of the first extracellular loop The amino acid sequences of those species whereby the modulators produced prominent efficacy enhancement (human, dog, rabbit) were compared to those that were minimally responsive (rat, mouse) to potentially identify regions of the A 3 AR that might participate in mediating the actions of the modulator compounds. We included the rat A 3 AR as a poor responding species in this analysis, since we found that both LUF6000 and LUF6096 produced no detectable efficacy enhancing activity in [ 35 S]GTPγS binding assays (P1 membranes) with the rat A 3 AR (not shown). As depicted in Fig. 8 , this analysis revealed that the first extracellular loop (EL1) region, composed of five amino acids of which four were conserved in human, dog, and rabbit (75G-I-T-I-H/Q/G79), was markedly different in mouse and rat and notably contained charged residues (E or K). Based on this analysis, assays were conducted with a stably transfected HEK 293 cell line expressing a mutated form of the human A 3 AR, named the mEL1-hA 3 AR, in which the EL1 region was changed to the mouse sequence (76Q-V-K-M-H80). A clonal cell line was selected that expressed the mEL1-hA 3 AR at levels similar to that of the wild-type human A 3 AR-expressing HEK 293 cell line. As determined in saturation equilibrium radioligand binding assays, mutation of EL1 of the human A 3 AR to the mouse sequence did not influence the binding affinity of [ 125 I]I-AB-MECA to either the high-(G protein-coupled) or low-(uncoupled) affinity states and also did not influence the fraction of receptors in the highaffinity state (Table 3) .
In [
35 S]GTPγS binding assays, LUF6096 increased the efficacy of Cl-IB-MECA (10 μM) with HEK 293 cell membranes expressing the mEL1-hA 3 AR to a similar extent as compared to assays with the wild-type human A 3 AR (Fig. 9) . However, the EC 50 of LUF6096 was reduced 17-fold, determined from [
35 S]GTPγS binding assays in which concentration-response curves with LUF6096 were conducted in the presence of 10 μM Cl-IB-MECA. As shown in Fig. 9 , LUF6096 did not reduce the extent of [ (Fig. 9) . The potency (EC 50 ) of LUF6096 to reduce binding to the mEL1-hA at (Fig. 9) . These results indicate that changing the EL1 region of the human A 3 AR to the mouse sequence results in a greater effect of LUF6096 to (i) reduce the potency of Cl-IB-MECA and (ii) slow [ 125 I]I-AB-MECA binding kinetics.
Molecular modeling
In an attempt to analyze the structural details of the EL1 region, we built homology models of the human A 3 AR, mouse A 3 AR, and mEL1-hA 3 AR and performed a conformational search of the extracellular loop areas. The models were based on the reported crystal structure of the human A 2A AR [26] . As part of the modeling, EL1 and EL2 were cooperatively refined due to their close proximity and the potential for interaction. Loop modeling is still a challenging Table 2 Influence of LUF6000 and LUF6096 on the rate of dissociation of [ Data are dissociation rate constants (mean ± SEM; n = 3-6) calculated for the slow (K 1 ) and fast (K 2 ) components, as described in BMaterials and methods* P < 0.05 vs. vehicle Table 1 that reports dissociation rate constants task due to marked flexibility, making it difficult to obtain unequivocal information. Figure 10 shows the top scoring conformations obtained for the three different receptors.
The following information regarding EL1 and EL2 was obtained from the analyses. The general structure of EL1 was predicted to be similar between the human and mouse receptors because of its short length (five residues) despite marked dissimilarity in the amino acid sequence in this region. In some cases, it formed a β-sheet with part of EL2, as observed in several human A 2A AR crystal structures [26, 32] . The EL2 residues predicted from the model to make contact with the EL1 sequence are different between the species: 162T-F-L-S-C-Q167 for the human A 3 AR and 163S-T-L-L-C-H168 for the mouse A 3 AR. Therefore, replacement of the EL1 region of the human A 3 AR with the mouse sequence affects the interaction pattern between the two loops in comparison with the native receptor, which could result in modification of EL2 structure and function of the mEL1-hA 3 AR. Notably, EL1 does not make direct contact with Cl-IB-MECA in the binding cavity while EL2 does, as shown from the Cl-IB-MECA docking pose reported in Fig. 10 . In fact, some EL2 residues have a role in shaping the binding cavity and stabilizing the ligand. For example, a phenylalanine that is conserved among ARs (F168 at the human A 3 AR) forms a π-π stacking interaction with the adenine core of the ligand in agreement with the binding mode of AR agonists in the A 2A AR crystallographic structures [32] . EL2 appears to be very flexible given the wide range of possible conformations it assumed during the search. At the human A 2A AR, EL2 is involved in three disulfide bridges that constrain its structure, while in the A 3 AR, only one disulfide is present. Therefore, the conformation of EL2 of the A 3 AR could be quite different from that of the A 2A AR.
Discussion
This study compared the modulatory activity of LUF6000 and LUF6096 at the A 3 AR from four different mammalian species (human, dog, rabbit, and mouse) expressed in HEK 293 cells. These ligands, which are currently under investigation in preclinical animal models [19, 20] , emerged from SAR studies of the [11] [12] [13] [14] [15] [16] [17] [18] . We demonstrate that the pharmacology of the modulators is unique for each of the species investigated. Most notably, both modulators showed weak efficacy enhancing activity on mouse A 3 ARs.
The observation that both LUF6000 and LUF6096 exert low efficacy-enhancing activity versus rodent A 3 ARs was not unexpected. Previous studies have documented that orthosteric pharmacology of rodent A 3 ARs differs substantially from other mammalian species, explained by a greater degree of sequence divergence that influences the orthosteric ligand binding pocket and receptor activation mechanisms [3, 4, 6] . The A 3 AR is known to be capable of stimulating G proteinindependent translocation of β-arrestin2 upon ligand binding that contributes to rapid desensitization of the receptor and may Amino acid residues that are conserved in species found to be responsive to both modulator compounds (human, dog, rabbit) but are not conserved in weakly responding species (rat, mouse) are highlighted in red. According to this criterion for comparison, marked variability was identified in the first extracellular loop region. Detailed amino acid sequence comparison of this region is shown in the lower left-hand section of the illustration. The dendrogram in the lower right-hand corner reveals that A 3 AR sequences from responsive and less responsive species cluster together. This diagram was prepared using the GPCRdb database (http://www.gpcrdb.org). Data are the ± SEM (n = 6). Parameters calculated with the mEL1-hA 3 AR were not significantly different from the wild-type human A 3 AR by Student's t test also lead to activation of additional intracellular signaling pathways [14] . Since LUF6000 has been reported to modulate β-arrestin translocation mediated by the human A 3 AR [14] , it would be interesting to compare activity of the modulator compounds on this signaling response in other species. Other notable species differences include a variable effect of the modulators to decrease agonist potency in the ]I-AB-MECA binding kinetics appears to be complex, whereby the on and off rates are influenced in a manner that results in slowed ligand-receptor complex formation but no change in binding at equilibrium. In general, the properties of the two different modulators were comparable. Both produced a similar degree of efficacy enhancement as well as effects on [
125 I]I-AB-MECA binding, and both displayed a similar activity profile among the different species of receptors. While the two different modulators are structurally dissimilar, the data suggest that they both likely interact with the same allosteric site on the receptor.
The mutagenesis studies suggest that the EL1 region of the A 3 AR participates in mediating the allosteric effect of Ribbon region corresponding to the mutated residues in EL1 is colored green. Docking pose of Cl-IB-MECA is shown in cyan LUF6096 to alter orthosteric ligand binding kinetics. It is possible that the EL1 region provides structural support that allows access of agonists to the orthosteric ligand binding site. Based on findings from the molecular modeling analyses of the extracellular loop regions, this may occur through interactions with EL2. These analyses predicted that EL2, which is much larger, can assume different conformations that are influenced by EL1, as shown by the formation of a β-sheet between the two loops in some cases. It is interesting that the EL1 region of the M 4 muscarinic receptor has been implicated to serve a similar function. Nawaratne and colleagues [35] identified that a single mutation of an isoleucine 93(2.65) of EL1 of the M 4 muscarinic receptor to a threonine residue selectively reduced the modulatory activity of the allosteric ligand LY2033298 to increase orthosteric agonist binding while leaving efficacy enhancing activity unchanged. Another mutagenesis study of the human A 3 AR by our group determined that specific amino acid residues in transmembrane regions 1, (asparagine 30(1.50) ), 2 (aspartic acid 58(2.50) ), 3 (aspartic acid 107(3.49) ), 5 (phenylalanine 182(5.43) ), and 7 (asparagine 274 (7.45) ) abolished the effect of the imidazoquinolinamine A 3 AR allosteric modulator DU124183 to decrease the rate of dissociation of [ 125 I]I-AB-MECA, implicating these regions as additional sites required for allosteric interactions [12] . All of these amino acid residues are conserved among the human, dog, rabbit, mouse, and rat sequences. In this earlier study, the effect of the mutations on functional enhancing activity was not addressed.
In conclusion, species variation in the actions of GPCR allosteric ligands has been underappreciated. Unlike the orthosteric binding site, allosteric domains of GPCRs are not subject to evolutionary pressures to accommodate endogenous ligands and can therefore exhibit greater variation between receptor subtypes and between species. The possibility for species variability lies not only with the ability of modulator compounds to bind to an allosteric site but also with the magnitude of allosteric interactions that influence signaling responses. This study provides evidence that allosteric pharmacology of the A 3 AR displays prominent species variability. This information is important for future development of this class of compounds for therapeutic use [8, 20] and should be considered when validating A 3 AR modulation by PAMs in animal models. It will be useful to focus efforts in future investigations to develop pan-species A 3 AR PAMs with minimal negative allosteric properties.
